Company Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Why Investors Should Care
Trades at a P/E of 0.1, below the sector median of 24.8.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -98.57% |
| 6 Months: | -91.87% |
| 3 Months: | -76.02% |
| 1 Month: | -17.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.77 · Oversold
P/E of 0.10 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GNPX Genprex, Inc. PHARMA | 3.54 | 0.10 | $2.90M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.97M | 4.68M | 3.35M | 3.52M | 4.49M |
| Operating Income | -719.86K | -751.30K | -1.18M | -715.12K | -686.63K | -6.04M | -2.20M | -2.17M | -3.70M | -2.38M | -5.58M | -4.38M | -2.78M | -5.31M | -3.99M | -3.44M | -5.31M | -5.77M | -6.17M | -9.26M | -8.04M | -7.79M | -6.00M | -6.52M | -4.32M | - | -3.97M | -4.68M | -3.35M | -3.52M | -4.49M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.97M | -4.68M | -3.34M | -3.51M | -4.49M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 455.55K | 284.39K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.96M | -4.67M | -3.80M | -3.79M | -4.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -719.86K | -751.30K | -1.18M | -715.10K | -694.00K | -6.06M | -2.19M | -2.16M | -3.70M | -2.38M | -5.57M | -4.37M | -2.77M | -5.31M | -3.99M | -3.44M | -5.31M | -5.76M | -6.14M | -9.20M | -7.98M | -7.75M | -5.97M | -6.50M | -4.32M | - | -3.96M | -4.67M | -3.80M | -3.79M | -4.46M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -285.56 | -187.00 | -110.00 | - | -14.08 |
| R&D Expense | 89.90K | 68.36K | 104.98K | 55.52K | 51.62K | 112.97K | 489.69K | 508.04K | 502.04K | 467.34K | 1.48M | 2.16M | 1.35M | 2.04M | 1.53M | 1.43M | 2.04M | 2.93M | 3.16M | 5.31M | 3.98M | 4.62M | 3.27M | 1.67M | 2.76M | - | 2.54M | 2.50M | 2.19M | - | 2.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | - |
| Operating Income | -4.13M | -3.31M | -12.36M | -10.68M | -17.96M | -20.67M | -23.83M | -31.06M | -21.17M | -15.52M |
| Net Income | -4.13M | -3.31M | -12.37M | -10.65M | -17.94M | -20.66M | -23.74M | -30.86M | -21.11M | -16.23M |
| R&D Expense | 354.88K | 289.93K | 971.43K | 1.97M | 7.30M | 8.97M | 11.51M | 17.62M | 10.54M | 9.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.91M | 1.26M | 9.27M | 3.53M | 31.37M | - | 39.41M | 34.57M | 29.95M | 25.09M | 10.67M | 4.12M | 10.16M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 21.47M | 7.53M | 2.08M | 8.36M |
| Cash & Equivalents | 234.22K | 1.60M | 161.25K | - | - | - | - | - | - | - | 20.95M | 6.74M | 1.60M | 7.83M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 0 | - | - | - | 34.85K | 0 | - | - |
| Total Liabilities | - | - | - | - | - | - | - | 2.38M | 2.15M | 2.46M | 2.81M | 3.25M | 2.50M | 2.20M |
| Current Liabilities | - | 285.66K | 830.96K | 387.82K | 510.68K | 450.72K | - | - | - | - | 2.81M | 3.25M | 2.50M | 2.17M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 393.74K | 1.62M | 428.57K | 8.88M | 3.02M | 30.92M | - | 37.02M | 32.41M | 27.49M | 22.27M | 7.42M | 1.62M | 7.96M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 1.09K | 1.35K | 9.87K | 149.61K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.25M | -2.17M | -6.85M | -6.92M | -13.94M | -14.28M | -17.62M | -24.74M | -17.92M | -15.31M |
| Investing Cash Flow | -89.53K | -63.42K | -103.32K | -946.90K | -2.34M | -83.80K | -59.73K | -71.21K | 774.64K | 0 |
| Financing Cash Flow | 2.71M | 793.97K | 15.39M | 1.27M | 41.59M | 25.68M | 6.43K | 10.59M | 12.01M | 21.54M |
| Capital Expenditure | -4.98K | -5.89K | -22.43K | -33.37K | -17.56K | -31.70K | -0 | - | - | - |
| Free Cash Flow | -1.25M | -2.18M | -6.87M | -6.95M | -13.95M | -14.32M | -17.62M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -254.3% | -773.3% | -139.3% | -352.4% | -58.0% | - | -106.6% | -416.1% | -1,303.0% | -203.8% |
| ROCE % | -254.3% | -772.9% | -139.2% | -353.3% | -58.1% | - | -107.0% | -418.8% | -1,306.9% | -194.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Fiduciary Trust Co | 0.43% | 3.55K | $12.25K |
| 2 | HRT Financial LP | 0.40% | 3.28K | $11.30K |
| 3 | Geode Capital Management, LLC | 0.33% | 2.74K | $9.46K |
| 4 | Vanguard Capital Management LLC | 0.20% | 1.65K | $5.70K |
| 5 | Cheviot Value Management, LLC | 0.12% | 1.00K | $3.45K |
| 6 | Engineers Gate Manager Lp | 0.12% | 949 | $3.27K |
| 7 | Mayflower Financial Advisors, LLC | 0.11% | 909 | $3.14K |
| 8 | Tower Research Capital LLC (TRC) | 0.02% | 129 | $445 |
| 9 | UBS Group AG | 0.02% | 204 | $703 |
| 10 | Harbour Investments, Inc. | 0.01% | 108 | $372 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GNPX
A biotech will discuss gene therapies for cancer and diabetes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPQnljMy1aeFVzREhqMGw2cnRuM3A5RVVjNm1mQUVIdE5NdTdOV3ZrQ0hIYjJCWXFUclF2Y2RvbkJwejlUZUt3aS1CR21hOGZuTEhRTnhJWFdsd1I3Uno3SFo0WkZ0YXRTLUNyRHFtTjZmX09XelJVRTgyYkE3M09QdE1RMmxVZDNoT0Zjaz…
Genprex Stock Price Forecast. Should You Buy GNPX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFAxd3dOaUhjYkh0YUFLeklRT0ZoS0UxdjM1azZBSDJZUlpTMzZ6aXpldnhUVVk4WHZ4QVJzSWpPUDZxWmdGY3B0Mw?oc=5" target="_blank">Genprex Stock Price Forecast. Should You Buy GNPX?</a> <fo…
$GNPX stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOQ3ZCSEx0Y1NJODVfdUNWT3JIR2NfX3ZNQUR6SjZ1N1RseUZLUDdBdkZJV2oyQXk3b2N5TnRtb09TQzYyaUtKM0hMbGlKNWFrVnVoUE96ZmM1U3ZacktMTUFsTW5veVhnQk9lNTlKNzVCTWhZMEx0S0t0MFQ2YW9JOUVmakJMamhuN3FEY2…
GNPX Stock Draws Trader Focus After Wild Price Swing - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE82UGhBdTNWbWZLcUlJUUdRc21OMDRGa0w0cUVST25KN3ozbnJDNFJHMFdMZGk4MHRlbnBFQzNEMkp2NF9mQlM3djVDZHBJdHBCRDN5QmowX2dSSHNlZ0JTdTdjS2l3NGhPVFB2a3RmQW9YQQ?oc=5" target="_blank">GNPX Stock Dr…
Genprex is scaling a diabetes therapy designed to deliver two genes to the pancreas - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSXp1ZTlTSUx6NXBCdGYyNXZoZWNZbEhheXlUNWx4VGh0ejkyWlVsVkFmTFgza3UxNWFCemNDMWhQMUhDcXhxSUJBZXROT1o1Ny1sR2VwTm1FaklQZ3hGalpLaXVwdXYtZzlIS2E4R3hfNTNINHdoY29wT0ZiTGxyM1RIRlFVMVhrT2ZoRE…
7/15/2026 Market Update - Winners: GNPX, CPHI, SOBR - Losers: ILLR, SNTI, SNWV - S&P 500: 0.4% - Trefis
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNX1F4TkxWQzU0YzR5eEYzbTNqd21xMjBSUF9Mb2QtMVptV1ZHU1dYeHU0d2U5YkRJbThsM0Z3ZFlwNzdGbS1PUVNrdGdVWTRhX24xMzdGVGo0US1yWnBQVVVIMUQ3VFRxc0NhaF9mcGp3Y1pXRC0wUWR3NEhpZFl0a1R6Y2F6ZE9wd3g3R0…
GNPX — Frequently Asked Questions
What is the current share price of Genprex, Inc. (GNPX)?
As of 2026-09-19 21:16 PDT, Genprex, Inc. (GNPX) trades at $3.54 on NasdaqCM. Its 52-week range is $3.42 to $924.00.
What is the market capitalisation of GNPX?
Genprex, Inc. (GNPX) has a market capitalisation of $2.90M on NasdaqCM.
What is the P/E ratio of GNPX?
GNPX trades at a trailing price-to-earnings (P/E) ratio of 0.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.12.
Is GNPX a good stock to buy?
This page provides a data-driven analysis of Genprex, Inc. (GNPX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.